4 assets in Immunoglobulin G4-Related Sclerosing Disease

Therapeutic assets addressing Immunoglobulin G4-Related Sclerosing Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bcma-Cd19 Ccar T Cells Immunoglobulin G4-Related Sclerosing Disease	Peking University People's Hospital	P2	CCC (53)
Filgotinib Immunoglobulin G4-Related Sclerosing Disease	UMC Utrecht	P2	CCC (53)
Mtm-H-001 Immunoglobulin G4-Related Sclerosing Disease	Beijing GoBroad Hospital	N/A	D (30)
Lvivo-Tavec400 Product Immunoglobulin G4-Related Sclerosing Disease	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Early P1	NR ()